Syndax Pharmaceuticals, Inc. (SNDX) Report Analysis
Corporate Events
Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer
2022-06-13 11:30:00
Syndax Pharmaceuticals, Inc. announced the appointment of Keith A. Goldan to the role of Chief Financial Officer, effective immediately. Mr. Goldan, who brings to Syndax nearly thirty years of leadership and operational experience at several pharmaceutical, biotechnology, and medical technology companies, most recently served as Chief Financial Officer at Optinose®, where he helped build the infrastructure to support the launch of XHANCE® (fluticasone propionate) in the United States. As Chief Financial Officer at Syndax, Mr. Goldan will oversee corporate finance and accounting, financial strategy, and investor relations. Mr. Goldan has served as Chief Financial Officer of numerous private and public biopharmaceutical companies from early stage through commercial stage, including Optinose, Fibrocell, NuPathe, PuriCore plc, and Biosyn. During his career, he led the successful execution of multiple initial public offerings and follow-on equity, rights, private placement, and debt offerings, as well as several merger and acquisition transactions. Mr. Goldan received a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from the Wharton School at the University of Pennsylvania.
Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 03:20 PM
2022-05-27 13:36:00
Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 03:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Syndax Pharmaceuticals, Inc. Presents at 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun-02-2022 12:30 PM
2022-05-26 00:00:00
Syndax Pharmaceuticals, Inc. Presents at 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun-02-2022 12:30 PM.
Syndax Pharmaceuticals, Inc. Presents at Citi Biopharma VIRTUAL Co-Panel Day, May-18-2022 01:30 PM
2022-05-14 10:29:00
Syndax Pharmaceuticals, Inc. Presents at Citi Biopharma VIRTUAL Co-Panel Day, May-18-2022 01:30 PM. Venue: New York, United States.
Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022
2022-05-02 11:00:00
Syndax Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022
Syndax Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 09, 2022
2022-05-02 11:00:00
Syndax Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 09, 2022
Syndax Pharmaceuticals, Inc. - Shareholder/Analyst Call
2022-03-29 20:02:00
AGM
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022
2022-03-29 20:02:00
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022, at 10:00 Eastern Daylight. Agenda: To consider election of three (3) Class III directors, each to serve a three-year term, an advisory vote on the compensation paid to our named executive officers, an advisory vote on the frequency of future advisory votes on the compensation paid to the named executive officers, to consider the ratification of the appointment of Deloitte & Touche LLP as Syndax's independent registered public accounting firm for the fiscal year ending December 31, 2022; and to consider other matters (if any).
Cowen Inc., 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun 02, 2022
2022-03-28 15:12:00
Cowen Inc., 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun 02, 2022.
Citigroup Inc., Citi Biopharma VIRTUAL Co-Panel Day, May 18, 2022
2022-03-17 05:21:00
Citigroup Inc., Citi Biopharma VIRTUAL Co-Panel Day, May 18, 2022. Venue: New York, United States.
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022
2022-02-08 07:31:00
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Syndax Pharmaceuticals, Inc. Announces Executive Changes
2022-02-03 21:01:00
Syndax Pharmaceuticals, Inc. announced that Michael A. Metzger, President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective February 3, 2022. Briggs W. Morrison, M.D., Chief Executive Officer, will transition to the role of President, Head of Research and Development (R&D). Mr. Metzger and Dr. Morrison will remain on the Company's Board of Directors. Both Mr. Metzger and Dr. Morrison joined Syndax together in 2015 with the goal of building a world-class oncology company. Prior to Syndax, Dr. Morrison served in several senior leadership roles in the industry, including as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, Head, Medical Affairs, Safety and Regulatory Affairs at Pfizer, and Vice President, Clinical Sciences, Oncology, at Merck & Co.
Syndax Pharmaceuticals, Inc. Announces Executive Changes
2022-02-03 21:01:00
Syndax Pharmaceuticals, Inc. announced that Michael A. Metzger, President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective February 3, 2022. Briggs W. Morrison, M.D., Chief Executive Officer, will transition to the role of President, Head of Research and Development (R&D). Prior to joining Syndax, Mr. Metzger served as President, Chief Executive Officer and a Director of Regado Biosciences through its merger with Tobira Therapeutics (acquired by Allergan). He has also served in senior leadership and business development roles at Mersana Therapeutics, Forest Laboratories (acquired by Allergan), and in various other industry and investment roles.
Syndax Pharmaceuticals, Inc. Enters into Amendment No. 1 to the Loan and Security Agreement
2021-12-23 21:03:00
On December 22, 2021, Syndax Pharmaceuticals, Inc. (the “ Company”) entered into Amendment No. 1 to the Company’s Loan and Security Agreement (the “ First Amendment”) with the several banks and financial institutions or entities from time-to-time party thereto (collectively, the “ Lender”) and Hercules Capital, Inc., in its capacity as administrative agent for itself and the Lender (in such capacity, the “ Agent”). The First Amendment amended that certain Loan and Security Agreement dated as of February 7, 2020 (the “ Existing Loan Agreement,” as amended by the First Amendment, the “ Loan Agreement”) among the Borrower, the Lender and the Agent. The First Amendment increases the amount that the Company may borrow by $50.0 million, from up to $30.0 million to up to $80.0 million, in multiple tranches. The First Amendment increases the second tranche (“ Tranche 2”) from $10.0 million to $30.0 million with $15.0 million being available at the Company’s option through April 30, 2022 and another $15.0 million being available at the Company’s option through November 30, 2022, which availability period will be extended to April 30, 2023 if the first $15.0 million is drawn prior to April 30, 2022. The First Amendment also provides for a third tranche of $30.0 million (“ Tranche 3”), which is available, subject to the Agent’s investment committee approval, through the Interest-Only Period. The Company’s only borrowings to date under the Loan Agreement are the first tranche of $20.0 million, which the Company drew upon the closing of the Loan Agreement on February 7, 2020.
Syndax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.
2021-12-15 00:00:00
Syndax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Security Name: Pre-Funded Warrants Security Type: Equity Warrant
Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $72.249886 million.
2021-12-15 00:00:00
Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $72.249886 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,945,000 Price\Range: $17.5 Discount Per Security: $1.05 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 1,142,856 Price\Range: $17.4999 Discount Per Security: $1.0499
Certain Common Stock of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022.
2021-12-15 00:00:00
Certain Common Stock of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022. These Common Stock will be under lockup for 61 days starting from 15-DEC-2021 to 14-FEB-2022. Details: The executive officers and directors and the stockholders of company’s outstanding securities have agreed that they will not offer, sell, contract to sell, pledge, or otherwise dispose of, directly or indirectly, or hedge our units, warrants, shares or any other securities convertible into or exchangeable or exercisable for company’s common shares, for a period of 60 days after the date of the final prospectus without the prior written consent of Goldman Sachs & Co. LLC and Cowen and Company LLC.
Certain Pre-Funded Warrants of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022.
2021-12-15 00:00:00
Certain Pre-Funded Warrants of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022. These Pre-Funded Warrants will be under lockup for 61 days starting from 15-DEC-2021 to 14-FEB-2022. Details: The executive officers and directors and the stockholders of company’s outstanding securities have agreed that they will not offer, sell, contract to sell, pledge, or otherwise dispose of, directly or indirectly, or hedge our units, warrants, shares or any other securities convertible into or exchangeable or exercisable for company’s common shares, for a period of 60 days after the date of the final prospectus without the prior written consent of Goldman Sachs & Co. LLC and Cowen and Company LLC.
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022.
2021-12-15 00:00:00
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022. These Restricted Stock Units will be under lockup for 61 days starting from 15-DEC-2021 to 14-FEB-2022. Details: The executive officers and directors and the stockholders of company’s outstanding securities have agreed that they will not offer, sell, contract to sell, pledge, or otherwise dispose of, directly or indirectly, or hedge our units, warrants, shares or any other securities convertible into or exchangeable or exercisable for company’s common shares, for a period of 60 days after the date of the final prospectus without the prior written consent of Goldman Sachs & Co. LLC and Cowen and Company LLC.
Certain Stock Options of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022.
2021-12-15 00:00:00
Certain Stock Options of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2022. These Stock Options will be under lockup for 61 days starting from 15-DEC-2021 to 14-FEB-2022. Details: The executive officers and directors and the stockholders of company’s outstanding securities have agreed that they will not offer, sell, contract to sell, pledge, or otherwise dispose of, directly or indirectly, or hedge our units, warrants, shares or any other securities convertible into or exchangeable or exercisable for company’s common shares, for a period of 60 days after the date of the final prospectus without the prior written consent of Goldman Sachs & Co. LLC and Cowen and Company LLC.
Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
2021-12-13 19:45:00
Syndax Pharmaceuticals, Inc. announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company's highly selective oral menin inhibitor. The data are being featured during an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting on Monday, December 13, 2021 at 3:15 p.m. ET. As of an October 18, 2021 data cutoff date, a total of 59 patients with a median of four prior therapies, including 42% who received a prior stem cell transplant and 59% who received prior venetoclax, were dosed in the Phase 1 portion of the trial. Across evaluable patients with mNPM1 (n=13) or MLLr (n=38) acute leukemia who received at least one dose of SNDX-5613, the overall response rate1 (ORR) was 55%, with a CR/CRh rate of 24% and nine patients proceeding to stem cell transplant (two patients achieving a CR with incomplete platelet recovery [CRp] with no evidence of minimal residual disease [MRD], and seven patients who achieved MRD- CR or CRh). The ORR in evaluable patients harboring an NPM1 mutation was 38% (5/13), with a CR/CRh rate of 23% (3/13). The ORR in evaluable patients harboring an MLL-rearrangement was 61% (23/38), with a CR/CRh rate of 24% (9/38). The overall MRD negative rate was 31% (16/51). Among those patients who achieved CR/CRh, 92% (11/12) were MRD negative, including 100% (3/3) of NPM1 patients and 89% (8/9) of MLLr patients. Median time to response for patients achieving a CR/CRh was two months. Median duration of response (DOR) was not reached, inclusive of patients who received stem cell transplant, and 6/12 patients who achieved CR/CRh had a duration of response greater than six months. SNDX-5613 was well-tolerated, with no discontinuations due to treatment-related adverse events observed in heavily pretreated patients. The only dose limiting toxicity observed was Grade 3 QT prolongation, which occurred in 7% (3/43) of patients treated at the four doses that met the study's pre-defined recommended Phase 2 dose criteria. Differentiation syndrome was reported in 14% of patients (8/59) with all cases being Grade 1 or 2 and readily managed with standard therapies. As data from the Phase 1 portion of the trial have continued to mature, the results have demonstrated consistent and compelling anti-leukemic activity with favorable tolerability in patients with both R/R MLLr and NPM1 acute leukemias. The following table summarizes select efficacy and safety data that has been presented by the Company throughout 2021.
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
2021-12-11 19:00:00
Syndax Pharmaceuticals, Inc. announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD) despite two or more prior lines of therapy. Axatilimab is the Company's anti-CSF-1R monoclonal antibody. A total of 40 patients with refractory disease who received a median of four prior systemic therapies, including ibrutinib, ruxolitinib, and belumosudil, were treated in the Company's Phase 1/2 trial of axatilimab. As of an October 22, 2021 data cutoff date, 31 patients treated at two of the doses being tested in the Company's ongoing AGAVE-201 global pivotal study were evaluable for response. A best ORR (complete response + partial response) of 72% (18/25) at 1mg/kg every two weeks and 50% (3/6) at 3mg/kg every four weeks was observed, for an ORR of 68% (21/31). Of note, responses were observed across a range of organ systems with difficult to treat manifestations such as lung (5/15), skin (3/28), and joints and fascia (16/24). 33% of patients reported clinically meaningful improvement in their symptoms via the Lee Symptom Scale. As of the data cutoff date, 43% (17/40) of patients remained on treatment. Axatilimab was well-tolerated with a favorable safety profile. The most common adverse events were consistent with on-target effects on liver enzyme pharmacology. There was no incidence of cytomegalovirus (CMV) or other viral reactivation, and no apparent increases in risk for infection. Enrollment is ongoing in the Company's global pivotal Phase 2 AGAVE-201 trial of axatilimab in patients with cGVHD, with topline data expected in 2023. The trial will evaluate the safety and efficacy of three doses and schedules of axatilimab. The primary endpoint will assess objective response rate based on the 2014 NIH consensus criteria for cGVHD, with key secondary endpoints including duration of response and improvement in modified Lee Symptom Scale score.
Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab
2021-12-09 21:05:00
Syndax Pharmaceuticals, Inc. announced that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody. In connection with closing, Incyte paid Syndax the $117 million upfront initial license fee, and Syndax closed on Incyte's $35 million equity investment in the company.
Syndax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $34.997896 million.
2021-12-09 00:00:00
Syndax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $34.997896 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,421,523 Price\Range: $24.62
Syndax Pharmaceuticals to Seek Acquisitions
2021-11-15 21:30:00
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) will seek acquisitions. Briggs W. Morrison Chief Executive Officer said during the Third Quarter 2021 Conference Call, "We anticipate we will be able to continue to expand our pipeline through product acquisitions or in-licensing of quality differentiated assets. We expect to remain among preferred partners of such transactions. I'll now turn the call over to Michael to review our financial results".
Syndax Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 15, 2021
2021-11-08 12:00:00
Syndax Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 15, 2021
Syndax Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 15, 2021
2021-11-08 12:00:00
Syndax Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 15, 2021
Syndax Pharmaceuticals, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-13-2021 03:15 PM
2021-11-04 13:24:00
Syndax Pharmaceuticals, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-13-2021 03:15 PM. Venue: Georgia World Congress Center, Atlanta, Georgia, United States. Speakers: Eytan Stein.
Syndax Pharmaceuticals, Inc. Announces Executive Changes
2021-10-04 20:01:00
On October 4, 2021, Daphne Karydas notified Syndax Pharmaceuticals, Inc. of her intention to resign as treasurer, principal financial officer and principal accounting officer of the Company, effective October 22, 2021, in order to pursue another opportunity. Ms. Karydas will remain with the Company to assist with the transition through the end of the year. Ms. Karydas’ resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company has appointed Alexander Nolte, the Company’s Vice President, Chief Accounting Officer, as its principal accounting officer and interim principal financial officer effective upon Ms. Karydas’ departure. Mr. Nolte will serve as the Company’s principal accounting officer and interim principal financial officer as the Company conducts a search for a new chief financial officer. Mr. Nolte, age 49, has served as the Company’s Vice President, Chief Accounting Officer since September 2021 and previously served as Vice President, Corporate Finance since February 2021 and as Corporate Controller since April 2017. Prior to that, Mr. Nolte served as Corporate Controller from July 2015 to April 2017 at CoLucid Pharmaceuticals, responsible for the financial operations of the company. From September 2013 to July 2015, Mr. Nolte served as Director of Revenue Recognition and International Accounting at Aegerion Pharmaceuticals. From March 2008 to September 2013, Mr. Nolte held several finance positions at Genzyme Corporation.
Syndax Pharmaceuticals, Inc. Announces Resignation of Daphne Karydas as Chief Financial Officer
2021-10-04 20:01:00
On October 4, 2021, Daphne Karydas notified Syndax Pharmaceuticals, Inc. of her intention to resign as chief financial officer, treasurer, principal financial officer and principal accounting officer of the Company, effective October 22, 2021, in order to pursue another opportunity. Ms. Karydas will remain with the Company to assist with the transition through the end of the year. Ms. Karydas’ resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company has appointed Alexander Nolte, the Company’s Vice President, Chief Accounting Officer, as its principal accounting officer and interim principal financial officer effective upon Ms. Karydas’ departure. Mr. Nolte will serve as the Company’s principal accounting officer and interim principal financial officer as the Company conducts a search for a new chief financial officer. Mr. Nolte, age 49, has served as the Company’s Vice President, Chief Accounting Officer since September 2021 and previously served as Vice President, Corporate Finance since February 2021 and as Corporate Controller since April 2017. Prior to that, Mr. Nolte served as Corporate Controller from July 2015 to April 2017 at CoLucid Pharmaceuticals, responsible for the financial operations of the company. From September 2013 to July 2015, Mr. Nolte served as Director of Revenue Recognition and International Accounting at Aegerion Pharmaceuticals. From March 2008 to September 2013, Mr. Nolte held several finance positions at Genzyme Corporation.
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
2021-09-27 10:00:00
Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody. Syndax and Incyte are seeking to develop axatilimab as a backbone therapy for patients with cGVHD as well as in additional immune-mediated diseases where CSF-1R-dependent monocytes and macrophages are believed to contribute to organ fibrosis. Syndax recently completed a Phase 1/2 trial of axatilimab in patients with cGVHD. Data from the Phase 1 portion of the trial highlighting the tolerability and high response rate of axatilimab in cGVHD patients refractory to multiple therapeutic agents were reported during an oral presentation at the American Society of Hematology Annual Meeting in December 2020. Updated results from the Phase 1 portion and preliminary results from the Phase 2 expansion portion of the study, which evaluated 1 mg/kg of axatilimab every two weeks, are expected to be presented at a medical meeting in the fourth quarter of 2021. Enrollment continues in the ongoing global pivotal Phase 2 AGAVE-201 trial of axatilimab monotherapy in patients with cGVHD, with topline data expected in 2023. The companies also plan to initiate additional trials of axatilimab in patients with cGVHD in 2022, including a Phase 2 trial in combination with a JAK inhibitor in patients with steroid-refractory cGVHD. Beyond cGVHD, Syndax plans to commence a Phase 2 proof of concept trial of axatilimab early next year in patients with IPF, a serious, life-limiting orphan disease for which axatilimab could represent a much-needed treatment option with a novel mechanism of action. Under the terms of the agreement, Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:50 profit share in the U.S., and Syndax will receive double-digit royalties on sales outside of the U.S. Syndax will retain the option to co-promote axatilimab for any approved indications in the U.S. In connection with the agreement, Syndax will receive an upfront payment of $117 million plus a $35 million equity investment, which will be purchased at $24.62 per share, a 30% premium to the volume weighted average price over the 10 days prior to September 24, 2021. Syndax will also be eligible to receive up to an additional $450 million in potential regulatory, development and commercial milestone payments. The companies will share development costs associated with global and U.S.-specific trials for all agreed upon trials at a rate of 55% (Incyte) and 45% (Syndax), with Incyte responsible for 100% of future development costs for trials that are specific to ex-U.S. countries. Syndax will fund the initial development of axatilimab in IPF and Incyte will have the option to co-fund late-stage development for this indication. The agreement between Syndax and Incyte, including the upfront payment and equity investment, is subject to clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act and will become effective as soon as these conditions have been met. Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Syndax.
Syndax Pharmaceuticals, Inc. - Special Call
2021-09-27 10:00:00
To discuss the Global Collaboration between Syndax Pharmaceuticals and Incyte to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Syndax Pharmaceuticals, Inc. announced that it expects to receive $34.997896 million in funding from Incyte Corporation
2021-09-24 00:00:00
Syndax Pharmaceuticals, Inc. announced a private placement of 1,421,523 shares at a price of $24.62 per share for gross proceeds of $35 million on September 24, 2021. The transaction will include participation from Incyte Corporation.
Syndax Pharmaceuticals, Inc. Appoints Martin H. Huber to Its Board of Directors
2021-09-15 20:01:00
Syndax Pharmaceuticals, Inc. announced the expansion of its Board of Directors to nine members with the appointment of Martin H. Huber, M.D., effective Sept. 15, 2021. Dr. Huber has over 20 years of academic, biotechnology, and pharmaceutical drug development experience, currently serving as the President of R&D and Chief Medical Officer of Xilio Therapeutics, Inc. Prior to joining Xilio in April 2020, Dr. Huber served as Senior Vice President, Chief Medical Officer at TESARO, Inc. from September 2015 until its January 2019 acquisition by GlaxoSmithKline plc, and once acquired, as Senior Vice President, Clinical, until April 2020. Prior to TESARO, Dr. Huber served as Vice President, Oncology Clinical Research at Merck Research Laboratories from 2012 to 2015.
Syndax Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 09:30 AM
2021-09-02 11:00:00
Syndax Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 09:30 AM. Venue: New Windsor, United States.
Syndax Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 09:45 AM
2021-08-30 10:00:00
Syndax Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 09:45 AM. Venue: New York, United States. Speakers: Briggs W. Morrison, CEO & Director.
Syndax Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 08:30 AM
2021-08-26 17:20:00
Syndax Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 08:30 AM. Speakers: Briggs W. Morrison, CEO & Director, Daphne Karydas, Chief Financial Officer, Michael A. Metzger, President, COO & Director.
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021
2021-08-10 13:03:00
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.
Syndax Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $30.984699 million.
2021-08-09 00:00:00
Syndax Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $30.984699 million. Security Name: Common Stock Securities Offered: 2,165,248 Transaction Features: ESOP Related Offering
Syndax Pharmaceuticals, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:30 AM
2021-08-04 12:33:00
Syndax Pharmaceuticals, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:30 AM. Speakers: Anjali Ganguli, Vice President Corporate Development, Briggs W. Morrison, CEO & Director, Daphne Karydas, Chief Financial Officer, Michael A. Metzger, President, COO & Director.
Syndax Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021
2021-08-02 11:00:00
Syndax Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021
Syndax Pharmaceuticals, Inc. to Report Q2, 2021 Results on Aug 09, 2021
2021-08-02 11:00:00
Syndax Pharmaceuticals, Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021
American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021
2021-07-31 11:04:00
American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021. Venue: Georgia World Congress Center, Atlanta, Georgia, United States.
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021
2021-07-01 10:09:00
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.
Fundamental Summary
Syndax Pharmaceuticals's financial reports for Q1 showed some underwhelming results. Specifically, their growth, value, and income factors indicate an execution challenge when it comes to generating exciting and consistent growth. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. Therefore, we assessed them with a rating of 54 and a UNDERPERFORM recommendation.
Syndax Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 37.17 million compared to USD 27.72 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.54 a year ago.
Business Description
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Sector Overview
Syndax Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Syndax Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 5.1 | -31.9% | 81 | |
| Net Cashflow | 124.4 | 16.6% | 50 | |
| Capital Expenditure | -0.1 | 0.0% | 74 | |
| Asset Turnover | 0.4 | 6.6% | 78 | |
| Free Cashflow | 0.2 | -67.8% | 41 |
* All values are TTM
The below chart reflects Syndax Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Syndax Pharmaceuticals's peer average final assessment score stands on 64.0, Syndax Pharmaceuticals's score is 54.
- SNDX
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Syndax Pharmaceuticals's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Syndax Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.
5D MA
18.61
50D MA
16.22
200D MA
17.44
MACD
0.72
RSI
16.48
STOCH
83.0
Balance Sheet Analysis
Several numbers from Syndax Pharmaceuticals's current balance sheet were concerning, in two areas in particular: Equity and Book Value Factors. Syndax Pharmaceuticals management produced disappointing equity metrics this period, which stood at 374.5, representing a -8.3% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Its equity movement component, therefore, received a grade of 41. Also, Syndax Pharmaceuticals publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 2.4 and represents -18.6% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 55. That said, one metric, Liabilities, stood out as strongly positive. Syndax Pharmaceuticals is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 47.7, representing 15.5% change from the previous period. These liabilities changes appear balanced compared to their peers and project the message that management is capable and focused on balancing asset growth, resource allocation, and growing liabilities. Therefore, we rated their liabilities movement with a score of 85. Therefore, it received a cautionary score of 58.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 422.2 | -6.1% | 68 |
| Liabilities | 47.7 | 15.5% | 85 |
| Price to Book | 2.4 | -18.6% | 55 |
| Cash & Equivalents | 188.8 | -15.0% | 55 |
| Equity | 374.5 | -8.3% | 41 |
The below chart describes Syndax Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Syndax Pharmaceuticals received a balance sheet score of 58, the average of its peers stands on 65.0.
- SNDX
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 16 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 18 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 20 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 23 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 38 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Overall, Syndax Pharmaceuticals's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. Syndax Pharmaceuticals did an excellent job managing its revenue efficiency this past period. Syndax Pharmaceuticals's revenue efficiency is 139.3 according to the metrics in the current filing, which represents a -0.3% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 87. Also, Syndax Pharmaceuticals's reported return on equity (ROE) ratio was 5.1, representing a change of -31.9%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 81. That said, one metric, EBITDA, stood out as strongly negative. Syndax Pharmaceuticals's EBIDTA now sits at 17.0 and represents -36.4% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its EBITDA movement, therefore, received a grade of 47. Its income statement, therefore, earned a score of 62.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 17.0 | -36.4% | 47 |
| Total Revenues | 139.3 | -0.3% | 87 |
| Return on Equity | 5.1 | -31.9% | 81 |
The below chart describes Syndax Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Syndax Pharmaceuticals received a income statement score of 62 , the average of its peers stands on 67.0.
- SNDX
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 16 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 18 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 23 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 38 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Syndax Pharmaceuticals's recently published cash flow conveys disappointing growth, particularly with respect to Free Cash flow and Net Cash Flow metrics. Syndax Pharmaceuticals did a poor job related to generating and maintaining strong free cash flow this period, which stood at 0.2, representing a -67.8% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. Their free cash flow situation is more concerning relative to their peers and competitors. Consequently, their free cash flow movement received a grade of 41. Also, Syndax Pharmaceuticals's net cash flow metrics were 124.4 according to their current filing, which represents a 16.6% change from the previous report. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Syndax Pharmaceuticals's stock price going forward. Consequently, their net cash flow movement received a grade of 50. At the same time, one {cash_flow} metric, Asset Turnover, was actually strongly positive. Syndax Pharmaceuticals is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.4, representing a 6.6% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Therefore, its asset turnover movement earned a score of 78. The company's cash flow, Therefore, earned a score of 57.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 124.4 | 16.6% | 50 |
| Capital Expenditure | -0.1 | 0.0% | 74 |
| Asset Turnover | 0.4 | 6.6% | 78 |
| Free Cashflow | 0.2 | -67.8% | 41 |
The below chart describes Syndax Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Syndax Pharmaceuticals received a cash flow score of 57, the average of its peers stands on 67.0.
- SNDX
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 16 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 18 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 23 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 38 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.